RE: Patient 3 ?10 Jun 2025 16:09
RNS 3rd June 2025:
Hemogenyx Pharmaceuticals plc is pleased to announce that the second patient has been successfully treated in the ongoing Phase I clinical trial of HG-CT-1, the Company's proprietary Chimeric Antigen Receptor T-cell (CAR-T) therapy for relapsed/refractory acute myeloid leukemia (R/R AML) in adults.
The treatment was well tolerated and met the trial's predefined initial safety criteria. Encouragingly, early indications of clinical efficacy are evident. The patient will continue to be monitored according to the FDA-approved trial protocol to assess whether the study's secondary endpoints are achieved.
Manufacturing of HG-CT-1 for the treatment of a third patient is currently underway.
As manufacturing is unique to each patient, one would assume the 3rd patient has already been selected for treatment